{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T10:05:17Z","timestamp":1742983517628,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":12,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071627716"},{"type":"electronic","value":"9781071627723"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_14","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"239-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Developing Therapeutic Splice-Correcting Antisense Oligomers for Adult-Onset Pompe Disease with c.-32-13T>G Mutation"],"prefix":"10.1007","author":[{"given":"Kristin A.","family":"Ham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell D.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May T.","family":"Aung-Htut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"2","key":"14_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.27.2.178","volume":"27","author":"M Mehler","year":"1977","unstructured":"Mehler M, DiMauro S (1977) Residual acid maltase activity in late-onset acid maltase deficiency. Neurology 27(2):178\u2013184","journal-title":"Neurology"},{"issue":"1\u20132","key":"14_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cccn.2005.05.025","volume":"361","author":"K Umapathysivam","year":"2005","unstructured":"Umapathysivam K, Hopwood JJ, Meikle PJ (2005) Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease. Clin Chim Acta 361(1\u20132):191\u2013198. https:\/\/doi.org\/10.1016\/j.cccn.2005.05.025","journal-title":"Clin Chim Acta"},{"issue":"9646","key":"14_CR3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372(9646):1342\u20131353. https:\/\/doi.org\/10.1016\/S0140-6736(08)61555-X","journal-title":"Lancet"},{"issue":"12","key":"14_CR4","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","volume":"3","author":"ML Huie","year":"1994","unstructured":"Huie ML, Chen AS, Tsujino S et al (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet 3(12):2231\u20132236","journal-title":"Hum Mol Genet"},{"issue":"4","key":"14_CR5","first-page":"887","volume":"56","author":"CF Boerkoel","year":"1995","unstructured":"Boerkoel CF, Exelbert R, Nicastri C et al (1995) Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 56(4):887\u2013897","journal-title":"Am J Hum Genet"},{"issue":"7","key":"14_CR6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","volume":"5","author":"N Raben","year":"1996","unstructured":"Raben N, Nichols RC, Martiniuk F et al (1996) A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum Mol Genet 5(7):995\u20131000","journal-title":"Hum Mol Genet"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","volume":"8","author":"EW Ottesen","year":"2017","unstructured":"Ottesen EW (2017) ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci 8:1\u20136. https:\/\/doi.org\/10.1515\/tnsci-2017-0001","journal-title":"Transl Neurosci"},{"issue":"1","key":"14_CR8","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.1038\/s41598-020-63461-2","volume":"10","author":"MT Aung-Htut","year":"2020","unstructured":"Aung-Htut MT, Ham KA, Tchan M et al (2020) Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease. Sci Rep 10(1):6702. https:\/\/doi.org\/10.1038\/s41598-020-63461-2","journal-title":"Sci Rep"},{"issue":"20","key":"14_CR9","doi-asserted-by":"publisher","first-page":"doi:10.3390\/ijm","DOI":"10.3390\/ijms20205030","volume":"20","author":"MT Aung-Htut","year":"2019","unstructured":"Aung-Htut MT, McIntosh CS, Ham KA et al (2019) Systematic approach to developing splice modulating antisense oligonucleotides. Int J Mol Sci 20(20):doi:10.3390\/ijms20205030","journal-title":"Int J Mol Sci"},{"issue":"5","key":"14_CR10","doi-asserted-by":"publisher","first-page":"doi:10.3390\/bio","DOI":"10.3390\/biomedicines9050552","volume":"9","author":"LL Flynn","year":"2021","unstructured":"Flynn LL, Mitrpant C, Adams A et al (2021) Targeted SMN exon skipping: a useful control to assess in vitro and in vivo splice-switching studies. Biomedicines 9(5):doi:10.3390\/biomedicines9050552","journal-title":"Biomedicines"},{"issue":"3","key":"14_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymgme.2012.09.010","volume":"107","author":"MI Nilsson","year":"2012","unstructured":"Nilsson MI, Samjoo IA, Hettinga BP et al (2012) Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab 107(3):469\u2013479. https:\/\/doi.org\/10.1016\/j.ymgme.2012.09.010","journal-title":"Mol Genet Metab"},{"issue":"4","key":"14_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ymgme.2006.12.006","volume":"90","author":"H Kallwass","year":"2007","unstructured":"Kallwass H, Carr C, Gerrein J et al (2007) Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. Mol Genet Metab 90(4):449\u2013452. https:\/\/doi.org\/10.1016\/j.ymgme.2006.12.006","journal-title":"Mol Genet Metab"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:07:40Z","timestamp":1677654460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":12,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_14","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}